Tavilermide

Summary

Tavilermide (CHEMBL3544981) is a phase-3 clinical-stage protein; indicated across 1 condition including dry eye syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Chemistry: 580.5 Da · C24H32N6O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544981
Name	Tavilermide
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	9808372
Molecular formula	C24H32N6O11
Molecular weight	580.5
InChIKey	DVJXNXPFYJIACK-ULQDDVLXSA-N

SMILES: C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]1C(=O)NCC(=O)O)CCCCN)CCC(=O)O

IUPAC name: 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid

Also known as: D-3, MIM-D3, Tavilermida, Tavilermide, TAVILERMIDE

Parent form; salt/anhydrous children: CHEMBL3545067

Patent coverage: 34 distinct patent families (94 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 80 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).